Results 71 to 80 of about 74,680 (298)

Antipsychotic Polypharmacy among Children and Young Adults in Office-Based or Hospital Outpatient Department Settings

Pharmacy, 2017
The purpose of the study was three-fold: (1) to estimate the national trends in antipsychotic (AP) polypharmacy among 6- to 24-year-old patients in the U.S.; (2) to identify frequently used AP agents and mental disorder diagnoses related to AP ...
Minji Sohn, Meghan Burgess, Mohamed Bazzi   +2 more
doaj   +1 more source

Utilization of Psychotropic Medications and Polypharmacy Among Adults in Jazan Region, Saudi Arabia

Indonesian Journal of Pharmacy, 2020
Globally, there has been a surge in the prevalence of mental health disorders, not excluding Saudi Arabia. The availability of newer psychotropic medications has led to increased prescribing and polypharmacy. In Saudi Arabia, exploration of the knowledge
Abdulkarim M. Meraya, Monira Alwhaibi, Mamoon H Syed, Ali Shwihi, Muath Mashraqi, Rina Tripathi, Yasser Buayti, Dhaifallah Moraya   +7 more
doaj   +1 more source

Prevalence of polypharmacy and associated adverse health outcomes in adult patients with chronic kidney disease: protocol for a systematic review and meta-analysis

Systematic Reviews, 2021
Background Polypharmacy, often defined as the concomitant use of ≥ 5 medications, has been identified as a significant global public health threat. Aging and multimorbidity are key drivers of polypharmacy and have been linked to a broad range of adverse ...
Ikechi G. Okpechi, Mohammed M. Tinwala, Shezel Muneer, Deenaz Zaidi, Feng Ye, Laura N. Hamonic, Maryam Khan, Naima Sultana, Scott Brimble, Allan Grill, Scott Klarenbach, Cliff Lindeman, Amber Molnar, Dorothea Nitsch, Paul Ronksley, Soroush Shojai, Boglarka Soos, Navdeep Tangri, Stephanie Thompson, Delphine Tuot, Neil Drummond, Dee Mangin, Aminu K. Bello   +22 more
doaj   +1 more source

Optimizing medication use in older adults with multimorbidity and polypharmacy.

, 2021
Background Globally, societies are ageing. In Switzerland, the population group of adults aged ≥ 65 years is projected to increase from around 17% in 2010 to a third of the population by the year 2050.
Jungo, Katharina Tabea
core  

Polypharmacy in elderly cancer patients : challenges and the way clinical pharmacists can contribute in resource-limited settings [PDF]

, 2019
The aim of this study was to address the problems associated with polypharmacy in elderly cancer patients and to highlight the role of pharmacists in such cases in resource‐limited settings.
Saval Khanal, Khanal, Saval, Shrestha, Sudip, Sudip Shrestha, Khanal, S, Shrestha, S, Shrestha, Sunil, Sunil Shrestha   +7 more
core   +1 more source

Nonadherence and uncontrolled arterial hypertension in Croatia—Insights from the May Measurement Month 2023 campaign and Hunting the silent killer programme

British Journal of Clinical Pharmacology, EarlyView.
Aims To determine the prevalence of non‐adherence to antihypertensive medicines and to identify demographic and behavioral factors associated with non‐adherence in subjects enrolled in the May Measurement Month (MMM) 2023, as part of the permanent public health action Hunting the silent killer.
Valerija Bralić Lang, Ana Soldo, Olgica Velkovski Škopić, Sunčana Vlah Tomičević, Tin Šaban, Andrej Belančić, Ana Jelaković, Josipa Josipović, Mihaela Marinović Glavić, Ivan Pećin, Luka Prgomet, Tajana Željković Vrkić, Bojan Jelaković   +12 more
wiley   +1 more source

Rational polypharmacy

Seizure, 1995
The development of assays for plasma antiepileptic drug concentrations has led to the discovery of many pharmacokinetic interactions, some causing drug intoxication and others resulting in ineffective drug concentrations. In the 1970s, a number of epileptologists began to argue that single drug therapy was desirable in the treatment of epilepsy and ...
openaire   +4 more sources

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Polypharmacy management by 2030: a patient safety challenge. [PDF]

, 2017
The SIMPATHY (Stimulating Innovation Management of Polypharmacy and Adherence in The Elderly) consortium have explored how healthcare management programmes can be implemented to improve medication safety and prevent patient harm by addressing the ...
Kempen, Thomas, McIntosh, Jennifer, Wilson, Martin, Michael, Nils, Harrison, Cathy, Kinnear, Moira, Alonso, Albert, SIMPATHY Consortium, Mair, Alpana, Fernandez-Llimos, Fernando, Hurding, Simon, The SIMPATHY consortium   +11 more
core  

Preva Lence Of Quantitative And Qualitative Polypharmacy In Older Adults With Alzheimer Dementia [PDF]

Geriatrics, Gerontology and Aging
BACKGROUND: Polypharmacy can be defined quantitatively or qualitatively. One of the concepts underlying the quantitative definition of polypharmacy is the use of two or more medications.
Patrícia Medeiros de Souza, Liana Tieko Evangelista Kusano, Leopoldo Luiz dos Santos Neto   +2 more
doaj   +1 more source